Parathyroid Gland Carcinoma
Associated Genetic Biomarkers
NCI Definition: A malignant tumor arising from the parenchymal cells of the parathyroid gland. It is associated with the symptoms of primary hyperparathyroidism, resulting from the excessive production of parathyroid hormone. Morphologically, the differential diagnosis from parathyroid gland adenoma may be difficult. A definitive diagnosis of carcinoma is made only in the presence of capsular invasion, vascular invasion, and/or perineural invasion. 
Parathyroid gland carcinomas most frequently harbor alterations in BRAF, NRAS, ZFHX3, RET, and PTEN .
BRAF V600E, BRAF Mutation, BRAF Exon 15 Mutation, BRAF Codon 600 Missense, and NRAS Q61R are the most common alterations in parathyroid gland carcinoma .
There are 2 clinical trials for parathyroid gland carcinoma, of which 1 is open and 1 is completed or closed. Of the trials that contain parathyroid gland carcinoma as an inclusion criterion, 2 are phase 2 (1 open).
SSTR1, SSTR2, and SSTR3 are the most frequent gene inclusion criteria for parathyroid gland carcinoma clinical trials .
Lutetium lu 177 dotatate, nilotinib, and paclitaxel are the most common interventions in parathyroid gland carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.